Natural product-derived therapy for Diabetic Kidney disease: Salvianolic acid A, isolated from Salvia Miltiorrhiza Bunge, decreases VEGF-B expression, inhibits lipid accumulation in Podocytes, promotes insulin signalling in Podocytes, induces insulin sensitivity, ameliorates renal dysfunction and alleviates diabetic kidney disease via down regulation of its target gene, 28/February/2017, 12.10 am

Natural product therapy for glucose homeostasis and TIIDM: Anthocyanin increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 28/May/2017, 12.03 am
May 27, 2017
Laminar shear stress therapy for Glaucoma: Laminar shear stress therapy increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma via down regulation of its target gene, 28/March/2017, 12.23 am
May 27, 2017
Show all

Introduction: What they say

A study from the Division of Vascular Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77 Stockholm, Sweden shows that “Reducing VEGF-B Signaling Ameliorates Renal Lipotoxicity and Protects against Diabetic Kidney Disease.” This research paper was published in the 9 February 2017 issue of the journal “Cell Metabolism” [One of the best research journals in “Metabolism” with an I.F of 17.565] by Prof. Ulf Eriksson and Annelie Falkevall and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Natural product-derived therapy for Diabetic Kidney disease: Salvianolic acid A, isolated from Salvia Miltiorrhiza Bunge, decreases VEGF-B expression, inhibits lipid accumulation in Podocytes, promotes insulin signalling in Podocytes, induces insulin sensitivity, ameliorates renal dysfunction and alleviates diabetic kidney disease via down regulation of its target gene


Significance of the study:

Given that: (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) diabetes is going to be one of the top 10 causes of death by 2030; (3) diabetic disease results in a number of health complications, including diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy; (4) one third of people with diabetes suffer from diabetic kidney disease (DKD); and one third of them will develop kidney failure; (5) life-long painful injection/drug treatment is required to treat DM; (6) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a way to remove accumulation of lipid in different tissues, such as skeletal muscle, heart, liver and kidney, that improve insulin signalling and sensitivity; (iii) a cheaper alternative to the existing expensive weight-loss drugs; (iv) a side-effect-free natural product-based drug; and (v) a way to cure, not just treat, diabetes.


What is known?

Prof.Ulf Erickson’s research team has recently shown that inhibition of VEGF-B in mice results in:(1) reduction of renal lipotoxicity; (2) increased insulin signalling in Podocytes; (3) inhibition of DKD-associated symptoms and pathophysiologies; and (4) amelioration of renal dysfunction. Further, they have shown that patients with DKD have increased levels of VEGF-B, suggesting that decreasing the expression of VEGF-B in DKD patients may alleviate DKD.


From Research findings to Therapeutic opportunity:

This study suggests, for the first time, a natural product based therapy for DKD. Salvianolic acid A, by increasing the expression of its target gene, it may decrease the expression of VEGF-B. Thereby, it may: (1) decrease lipid accumulation in kidneys; (2) increase insulin signalling in Podocytes; (3) improve DKD-associated pathophysiologies, such as proteinuria; and (4) ameliorate kidney dysfunction (Fig.1).

Figure 1 Mechanistic insights into how Salvianolic acid A ameliorates Diabetic kidney disease (DKD)

Thus, pharmacological formulations encompassing “Salvianolic acid A or its analogs either alone or in combination with other drugs” may be used to treat DKD.

[easy_payment currency=”USD”]price-300


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Salvianolic acid A decrease the expression of VEGF-B to prevent DKD?

Amount: $300#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com/

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L., Natural product-derived therapy for Diabetic Kidney disease: Salvianolic acid A, isolated from Salvia Miltiorrhiza Bunge, decreases VEGF-B expression, inhibits lipid accumulation in Podocytes, promotes insulin signalling in Podocytes, induces insulin sensitivity, ameliorates renal dysfunction and alleviates diabetic kidney disease via down regulation of its target gene, 28/February/2017, 12.10 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.